Hansa Raises More Cash For Pipeline With Genovis Stake Sale

16 Apr 2019

The Swedish group has sold its stake in Genovis, raising about $9.6m that will help advance lead candidate imlifidase.

SwedishNotes — Hansa cashes in on Genovis stake • Source: Shutterstock

The rest of 2019 is looking busy for Hansa Biopharma AB and the biotech has divested its equity holding in fellow Swedish group Genovis AB to help fund its pipeline of therapies for rare diseases.

The Lund-headquartered group, which specializes in immunomodulatory enzyme technology for rare immunoglobulin G (IgG)-mediated diseases, has sold its entire stake in Genovis, a developer of enzymatic research tools, generating gross proceeds of SEK89m, about $9.6m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

14 May 2025

• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

14 May 2025

• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

14 May 2025

• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

14 May 2025

• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

14 May 2025

• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.